TriSalus Life Sciences, Inc. Warrant 2023-04.08.2028 on TriSalus Life Sciences
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.02 USD
−30.05 M USD
29.43 M USD
30.35 M
About TriSalus Life Sciences, Inc.
Sector
Industry
CEO
Mary T. Szela
Website
Headquarters
Westminster
Founded
2020
Identifiers
3
ISIN US89680M1190
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.
Displays a symbol's price movements over previous years to identify recurring trends.